Pulsenmore Secures FDA Approval for ES Device, Expands Key Partnerships, and Reports Reduced Annual Loss

summarizeSummary

Pulsenmore Ltd. announced FDA approval for its Pulsenmore ES device, a new $9 million agreement with Clalit Health Services, and a significant reduction in its 2025 net loss, largely due to a $9.6 million settlement with GE Healthcare.

check_boxKey Events

• FDA Approval for Pulsenmore ES Device

  The company received FDA approval for its Pulsenmore ES home ultrasound device as a Class II device at the end of October 2025, enabling its commercialization in the United States.

• New $9M Agreement with Clalit Health Services for Pulsenmore FC

  An addendum to an existing agreement with Clalit Health Services, Israel's largest HMO, was signed on January 21, 2026, for an 18-month pilot period for the Pulsenmore FC device, followed by a 5-year commitment for a minimum of 2,000 units annually, totaling $9 million.

• GE Healthcare Settlement Boosts 2025 Revenue

  A settlement agreement with GE Precision Healthcare LLC in August 2025 resolved prior disputes, resulting in $9.6 million in recognized revenue for 2025 and the termination of GEHC's remaining exclusive distribution rights.

• Significant Reduction in Annual Losses

  Net loss for the year ended December 31, 2025, decreased to $5.0 million from $11.5 million in 2024, and operating loss decreased to $3.8 million from $13.2 million, primarily driven by the GE Healthcare settlement.

auto_awesomeAnalysis

Pulsenmore Ltd. has achieved significant milestones, including FDA approval for its Pulsenmore ES device, which is crucial for its expansion into the U.S. market. The company also finalized a substantial $9 million agreement with Clalit Health Services for its Pulsenmore FC device, signaling strong commercial traction. While the reported net and operating losses for 2025 decreased significantly, this improvement was largely driven by a one-time $9.6 million revenue from a settlement with GE Healthcare. The company continues to face operational challenges and geopolitical risks due to its base in Israel, including key personnel serving in reserve duty, necessitating a business continuity plan. Despite these risks and the ongoing need for additional capital, the regulatory approval and new commercial agreements provide a strong foundation for future growth.